Literature DB >> 22046943

Diagnosis and management of osteomyelitis.

John Hatzenbuehler1, Thomas J Pulling.   

Abstract

The incidence of chronic osteomyelitis is increasing because of the prevalence of predisposing conditions such as diabetes mellitus and peripheral vascular disease. The increased availability of sensitive imaging tests, such as magnetic resonance imaging and bone scintigraphy, has improved diagnostic accuracy and the ability to characterize the infection. Plain radiography is a useful initial investigation to identify alternative diagnoses and potential complications. Direct sampling of the wound for culture and antimicrobial sensitivity is essential to target treatment. The increased incidence of methicillin-resistant Staphylococcus aureus osteomyelitis complicates antibiotic selection. Surgical debridement is usually necessary in chronic cases. The recurrence rate remains high despite surgical intervention and long-term antibiotic therapy. Acute hematogenous osteomyelitis in children typically can be treated with a four-week course of antibiotics. In adults, the duration of antibiotic treatment for chronic osteomyelitis is typically several weeks longer. In both situations, however, empiric antibiotic coverage for S. aureus is indicated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22046943

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  68 in total

Review 1.  Nanostructured platforms for the sustained and local delivery of antibiotics in the treatment of osteomyelitis.

Authors:  Vuk Uskokovic
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2015       Impact factor: 4.889

Review 2.  Role of nuclear medicine imaging in evaluation of orthopedic infections, current concepts.

Authors:  Alexandra Seltzer; Ryan Xiao; Michelle Fernandez; Rohit Hasija
Journal:  J Clin Orthop Trauma       Date:  2019-04-26

3.  In vitro analysis of nanoparticulate hydroxyapatite/chitosan composites as potential drug delivery platforms for the sustained release of antibiotics in the treatment of osteomyelitis.

Authors:  Vuk Uskoković; Tejal A Desai
Journal:  J Pharm Sci       Date:  2013-12-30       Impact factor: 3.534

Review 4.  Staphylococcus aureus pathogenesis in diverse host environments.

Authors:  Divya Balasubramanian; Lamia Harper; Bo Shopsin; Victor J Torres
Journal:  Pathog Dis       Date:  2017-01-01       Impact factor: 3.166

5.  Development of a Novel and Rapid Antibody-Based Diagnostic for Chronic Staphylococcus aureus Infections Based on Biofilm Antigens.

Authors:  Janette M Harro; Mark E Shirtliff; William Arnold; Jennifer M Kofonow; Chad Dammling; Yvonne Achermann; Kristen Brao; Javad Parvizi; Jeff G Leid
Journal:  J Clin Microbiol       Date:  2020-04-23       Impact factor: 5.948

Review 6.  Staphylococcal Osteomyelitis: Disease Progression, Treatment Challenges, and Future Directions.

Authors:  Nicola Kavanagh; Emily J Ryan; Amro Widaa; Gillian Sexton; Jerome Fennell; Sadhbh O'Rourke; Kevin C Cahill; Cathal J Kearney; Fergal J O'Brien; Steven W Kerrigan
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

7.  The association between chronic osteomyelitis and increased risk of diabetes mellitus: a population-based cohort study.

Authors:  S-Y Lin; C-L Lin; C-H Tseng; I-K Wang; S-M Wang; C-C Huang; Y-J Chang; C-H Kao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-07       Impact factor: 3.267

8.  Osteogenic and antimicrobial nanoparticulate calcium phosphate and poly-(D,L-lactide-co-glycolide) powders for the treatment of osteomyelitis.

Authors:  Vuk Uskoković; Charles Hoover; Marija Vukomanović; Dragan P Uskoković; Tejal A Desai
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2013-04-13       Impact factor: 7.328

9.  Enhanced eradication of intracellular and biofilm-residing methicillin-resistant Staphylococcus aureus (MRSA) reservoirs with hybrid nanoparticles delivering rifampicin.

Authors:  Pengbo Guo; Hui Yi Xue; Bettina A Buttaro; Ngoc T Tran; Ho Lun Wong
Journal:  Int J Pharm       Date:  2020-08-30       Impact factor: 5.875

Review 10.  Nanoparticulate drug delivery platforms for advancing bone infection therapies.

Authors:  Vuk Uskoković; Tejal A Desai
Journal:  Expert Opin Drug Deliv       Date:  2014-08-11       Impact factor: 6.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.